We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.
Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.
first to design and bring stereopure and allele-specific medicines to clinic
programs by end of 2018
initiated in 2017
nucleic acid modalities being advanced with Wave stereopure chemistry
therapeutic areas under active investigation